The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study
Research output: Contribution to journal › Journal article › Research › peer-review
There is only very limited documentation of the efficacy and safety of high-dose subcutaneous birch pollen immunotherapy (IT) in double-blind, placebo-controlled (DBPC) studies. Birch pollen is a major cause of allergic morbidity in northern Europe and in eastern parts of North America.
| Original language | English |
|---|---|
| Journal | Allergy |
| Volume | 57 |
| Issue number | 4 |
| Pages (from-to) | 297-305 |
| Number of pages | 9 |
| ISSN | 0105-4538 |
| Publication status | Published - Apr 2002 |
- Adult, Allergens, Antibody Specificity, Betula, Conjunctivitis, Allergic, Desensitization, Immunologic, Dose-Response Relationship, Immunologic, Double-Blind Method, Female, Follow-Up Studies, Humans, Immunoglobulin E, Male, Middle Aged, Pain Measurement, Phytotherapy, Pollen, Rhinitis, Allergic, Seasonal, Seasons, Sensitivity and Specificity, Severity of Illness Index, Treatment Outcome
Research areas
ID: 50845610